The Chicago Entrepreneur

: NeoGenomics stock plunges more than 20% as CEO departs after disappointing quarter

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shares down more than 20% in after-hours trading.

Previous post Market Snapshot: Dow, S&P 500 finish higher for third trading day on investor optimism about Russia-Ukraine
Next post ESG’s Russia Test: Trial by Fire or Crash and Burn?